Unresectable, locally advanced/metastatic Renal Cell Carcinoma with clear cell component (with or without sarcomatoid features) ie, Stage IV Renal Cell Carcinoma

Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy.

Previous nephrectomy or metastasectomy (the excision of one or more metastases) is allowed. PD on or after anti-PD-1/L1 therapy as 1st or 2nd line in adv/mets setting or as adjuvant treatment with progression on or within 6 months of last dose. Measurable disease by RECIST KPS > or – to 70%

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy.

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

Learn More